Association of Paediatric Emergency Medicine

**1468 TRANEXAMIC ACID IN PAEDIATRIC MAJOR TRAUMA: A TARN DATA ANALYSIS 2008–2020**

1 Harriett Thorpe, 2 Mark Lyttle, 3 Damian Roland, 4 Stephen Mullen, 5 Charlotte Sloane, 6 Omar Bouamra, 7 Carl Marinowitz.
8 NHS; 9 Bristol Royal Hospital for Children; 10 University Hospital of Leicester; 11 Royal Belfast Hospital for Sick Children; 12 TARN

10.1136/archdischild-2021-rcpch.665

**Background** Tranexamic Acid (TXA) is an anti-fibrinolytic agent that promotes haemostasis and counteracts coagulopathy in trauma. A wealth of research supports TXA use in adults, yet no large trials have been performed in paediatric populations. The RCPCH in 2012 advocated TXA use in paediatric trauma, recommending future evaluation of outcomes utilising the Trauma Audit and Research Network (TARN).

**Objectives** To describe TXA use in paediatric trauma over time, exploring association with best practice statements and evidence from adult trials. Primary outcome was to determine change in prevalence of use over time. Secondary outcomes captured details or impact of change, including thrombotic events, blood product use, surgical intervention, and evaluation of injury patterns.

**Methods** Retrospective analysis of TARN data between 2008–2020 for patients under 16 years in England and Wales, with no clinical exclusions.

A time series analysis was performed, with descriptive statistics given as mean (95% CI) or median (IQR).

**Results** 27,385 patients were included of which 18,535 (67.7%) were male. 7804 (28.5%) were aged 12–15, 6966 (25.4%) aged 6–11, 6570 (24%) aged 2–5 and 6045 (22.1%) under 1. Overall mortality within 30 days was 799 (2.9%).

TXA use increased year on year, from 25 (1.2%) in 2012 to 196 (10.1%) in 2020. Apart from an initial rapid rise in use in 2012–2013, no other annual progression showed a disproportionate increase. There was no change in 30-day mortality rate over time, ranging between 2.1% (in 2015) and 3.3% (in 2016). Change over time analysis showed no significant increase in thrombotic complications. In 2012 data revealed 4 (0.2%) thrombotic events compared to 2 (0.1%) in 2020, with a tenfold increase in TXA over same time period.

In total, 1346 (4.9%) patients received TXA, of which 735 (54.6%) were aged 12–15. Road traffic collisions (64%) and penetrating injuries (12.7%) were the commonest mechanisms of injury in those receiving TXA. In relation to trauma severity, the median Injury Severity Score in those treated with TXA was 20 [IQR 10–33], compared to 9 [IQR 9–16] in untreated patients; 829 (61%) of those treated with TXA were admitted to ICU, compared to 4849 (18.6%) without. Blood products were transfused in 245 (18.2%) patients receiving TXA compared to 110 (0.4%).

**Conclusions** We have demonstrated consistent increases in proportional use of TXA over time since the RCPCH statement in 2012, with no change in mortality. Despite significant increase in TXA use, the incidence of thrombotic events has remained stable. Within the constraints of the small rate of adverse events in this large cohort, there is no evidence to suggest harm following TXA treatment.

TXA is more likely to be given in those aged 12–15 years. This may be explained by different trauma patterns, with road traffic accidents and penetrating injuries more common in older children. Administration of blood products and ICU admission were strongly considered with administration of TXA. Further analyses of change over time are ongoing for secondary outcome analyses.

Association of Paediatric Palliative Medicine

**1469 DEVELOPMENT AND USE OF SYMPTOM MANAGEMENT PLANS IN GUIDING CARE OF CHILDREN REFERRED TO A TERTIARY PALLIATIVE CARE SERVICE**

1 Anna Chadwick, 2 Bhunik Patel, 3 Laura Nohavicka, 4 Myra Bluebond-Langner. 5 Royal Marden Hospital and Shooting Stars Hospice; 6 Great Ormond Street Hospital; 7 UCL School of Life and Medical Sciences, Faculty of Population Health Sciences UCL Great Ormond Street Institute of Child Health Population, Policy and Practice Research and Teaching Department Louis Dundas Centre for Children’s Palliative Care

10.1136/archdischild-2021-rcpch.666

**Background** The number of children living with life limiting conditions (LLC) has increased over the last 17 years with a current prevalence in the UK of 66.1 per 10000. These children often require tertiary palliative care input for management of symptoms. For many, particularly those at the end of life, specialist palliative care teams develop individual symptom management plans and/or syringe driver plans (SMP/SDP) to guide management of pain and distressing symptoms such as breathlessness, nausea and vomiting.

There is no national guidance on how and when such plans should be used, and their implementation varies across the country. The National Institute of Clinical Excellence (NICE) recommends that an agreed treatment plan should be used for children in the last hours or days of life, but does not specify use of symptom management plans prior to this.

**Objectives** To identify the development and use of SMP/SDP in management of symptoms in children referred to a tertiary palliative care service based in a tertiary paediatric hospital, with particular attention medications used at the end of life (EoL).

**Methods** Seven month (February-August 2020) prospective, comparative study of all children referred to a tertiary palliative care service including: recording of all referrals with number and type of medications prescribed in the SMP/SDP and used by the patient at the EoL.

**Results** 102 patients were referred to the tertiary palliative care service over the study period. This included new referrals for all non-oncological conditions and all oncology patients who required a SMP including those oncology patients who were referred to oncology outreach service, a part of the palliative care service, but who may not have required palliative care input at the time of referral. The majority of referrals were oncology (25%; 25/102), followed by cardiology (17.6%; 18/102), genetics (11.8%; 12/102) and metabolic (10.8% 11/102).

87 SMPs were written for a total of 58 patients. 26 patients died without a SMP 43 patients were managed with a SMP/SDP at the EoL. The median number of medications included in a SMP was 13 (range 3–32), with 2 medications (range 0–14) used at EoL. The median number prescribed in SDPs was 6 (range 2–10), with 2 drugs used at EoL (range 0–7). The most common medications prescribed and used were opiates followed by midazolam. The most common